Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: post hoc analysis of the EMPA-REG OUTCOME trial

Citation
Verma S, Sharma A, Zinman B, et al. Diabetes Obes Metab 2020;22:1141–50.